CD38 and plasma cell myeloma: Despite major therapeutic advances over the past two decades with proteasome inhibitors, immunomodulatory drugs (IMiDs), and monoclonal antibodies targeting CD38, multiple myeloma remains largely incurable, with most patients eventually experiencing disease relapse and drug resistance.